Oncolix Inc logo

ONCX - Oncolix Inc Share Price

$0 0.0  0.0%

Last Trade - 30/07/20

Micro Cap
Market Cap £8.73k
Enterprise Value £4.66m
Revenue £n/a
Position in Universe th / 6359
Unlock ONCX Revenue
Relative Strength (%)
1m +92.7%
Volume Change (%)
10d / 3m
Price vs... (%)
52w High 0.000
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st Dec 2012 2013 2014 2015 2016 2017 2018E 2019E CAGR / Avg
0.000 0.000 0.020 0.000 0.000 0.000
Balance Sheet
FINANCIAL BRIEF: : For the nine months ended 30 September 2018, Oncolix Inc revenues was not reported. Net loss applicable to common stockholders increased from $2.1M to $6.8M. Higher net loss reflects Interest expense on convertible notes increase from $1.3M to $3.1M (expense), Research and development expenses increase from $153K to $379K (expense). Basic Earnings per Share excluding Extraordinary Items decreased from -$0.02 to -$0.07.
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History


ONCX Revenue Unlock ONCX Revenue

Net Income

ONCX Net Income Unlock ONCX Revenue

Normalised EPS

ONCX Normalised EPS Unlock ONCX Revenue

PE Ratio Range

ONCX PE Ratio Range Unlock ONCX Revenue

Dividend Yield Range

ONCX Dividend Yield Range Unlock ONCX Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2020
31st Dec 2021
Est. Long Term Growth Rate: Net Profit
Net Profit
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
ONCX EPS Forecasts Unlock ONCX Revenue
Profile Summary

Oncolix, Inc., formerly Advanced Environmental Petroleum Producers Inc., is a clinical-stage biopharmaceutical company. The Company is primarily focused on the development of Prolanta, a biological drug for the treatment of cancer. The Company’s initial focus is ovarian cancer, and commenced a Phase I clinical trial of Prolanta for the treatment of ovarian cancer. Prolanta is effective in the treatment of breast, uterine, prostate and other cancers. The Company‘s Prolanta is a genetically modified form of human prolactin, a hormone associated with various types of cancers. Prolanta is designed to bind to the prolactin receptor on cells to block the effects of human prolactin. Human prolactin has documented to cause cancer cell proliferation by interacting with cancer cells. The Company has conducted animal studies to determine the efficacy of Prolanta in treating breast and ovarian cancers.

Last Annual December 31st, 2017
Last Interim September 30th, 2018
Incorporated June 13, 2013
Public Since May 5, 2015
No. of Shareholders: n/a
No. of Employees: n/a
Sector Healthcare
Industry Biotechnology & Medical Research
Exchange OTC Markets Group
Shares in Issue 114,227,936
Free Float (0.0%)
Eligible for
ONCX Share Price Performance
Share Price
Bid - Ask
Low - High
Day's Change
Avg Volume
Open - Close
Range (12m)
Latest News for ONCX
Upcoming Events for ONCX
Frequently Asked Questions for Oncolix Inc
What is the Oncolix Inc share price?

As of 30/07/20, shares in Oncolix Inc are trading at $0, giving the company a market capitalisation of £8.73k. This share price information is delayed by 15 minutes.

How has the Oncolix Inc share price performed this year?

Shares in Oncolix Inc are currently trading at $0 and the price has moved by 0% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Oncolix Inc price has moved by -6.12% over the past year.

What are the analyst and broker recommendations for Oncolix Inc?

There are no analysts currently covering Oncolix Inc.

When will Oncolix Inc next release its financial results?

Oncolix Inc is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2019-09-30
What is the Oncolix Inc dividend yield?

Oncolix Inc does not currently pay a dividend.

Does Oncolix Inc pay a dividend?

Oncolix Inc does not currently pay a dividend.

When does Oncolix Inc next pay dividends?

Oncolix Inc does not currently pay a dividend.

How do I buy Oncolix Inc shares?

To buy shares in Oncolix Inc you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Oncolix Inc?

Shares in Oncolix Inc are currently trading at $0, giving the company a market capitalisation of £8.73k.

Where are Oncolix Inc shares listed? Where are Oncolix Inc shares listed?

Here are the trading details for Oncolix Inc:

Country of listing: United States
Exchange: OTC
Ticker Symbol: ONCX
What kind of share is Oncolix Inc?

We were not able to load our ranking data for Oncolix Inc

Is there a Oncolix Inc share price forecast 2020?

We were not able to load any forecast data for Oncolix Inc.

How can I tell whether the Oncolix Inc share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Oncolix Inc. Over the past six months, the relative strength of its shares against the market has been 2.09%. At the current price of $0, shares in Oncolix Inc are trading at 18.76% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Oncolix Inc PE Ratio?

We were not able to find PE ratio data for Oncolix Inc.

Who are the key directors of Oncolix Inc?

We were unable to find the directors for Oncolix Inc.

Who are the major shareholders of Oncolix Inc?

Here are the top five shareholders of Oncolix Inc based on the size of their shareholding:

Health Sciences Center, L.L.C. Corporation
Percentage owned: 42.02% (48.0m shares)
Biovectra, Inc. Corporation
Percentage owned: 8.75% (10.00m shares)
Redman (Michael Thomas) Individual Investor
Percentage owned: 3.85% (4.40m shares)
Mallinckrodt plc Corporation
Percentage owned: % (n/a shares)
Texas Treasury Safekeeping Trust Co. Investment Advisor
Percentage owned: % (n/a shares)
Similar to ONCX
© Stockopedia 2020, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.